HOERSHOLM, Denmark, May 29, 2002 (PRIMEZONE) -- The Danish Shareholders Association has announced the results of the Danish Corporate Governance Award 2002. The Award is based on 17 criteria around Corporate Governance and information policy in publicly traded Danish companies. Pharmexa ranks fifth, placing it among the highest ranked listed companies in Denmark. Among the 10 highest ranked companies, Pharmexa is by far the smallest company and one of just 3 companies not belonging to the KFX index. Pharmexa is the highest ranked member of the KVX index (the Danish growth index) in the survey.
Chief Financial Officer and responsible for Investor Relations Jakob Schmidt said: "We are proud of the high ranking, placing us in front of some of the largest, most well respected companies in Denmark. Since we went public two years ago, we have worked on becoming a shareholder friendly company. Our Corporate Governance policy as well as our Information Policy mirror this ambition and can be found in our 2001 Annual Report as well as on our homepage www.pharmexa.com."
Note to editors: Pharmexa A/S (CSE:PHARMX) is a leading company in the field of therapeutic vaccines for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(TM) pharmaccine technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases. Pharmexa's research and development programs are targeted towards breast cancer, asthma, bone degeneration, allergy and neurodegenerative diseases. The Pharmexa Group has entered into collaborative agreements with Lexigen/Merck KGaA, Ferring, Schering-Plough, H. Lundbeck, NeuroSearch, GlaxoSmithKline, Zycos, Epimmune and AstraZeneca. The Group has 153 employees. More information on Pharmexa can be found on www.pharmexa.com.
Should you have any questions or queries please do not hesitate to contact Noonan Russo Presence on +44 20 7726 4452.